Recruitment

Recruitment Status
Completed
Estimated Enrollment
144

Inclusion Criteria

Stable dosing of psychotropic drugs for 5 half-lives or greater
Age 3-25 years
Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
Stable dosing of psychotropic drugs for 5 half-lives or greater
Age 3-25 years
Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V

Exclusion Criteria

Use of lithium, riluzole or other known modulators of ERK activation
Diagnosis of schizophrenia, another psychotic disorder, bipolar disorder, or alcohol or other substance abuse based on DSM-V criteria
Use of lithium, riluzole or other known modulators of ERK activation
Diagnosis of schizophrenia, another psychotic disorder, bipolar disorder, or alcohol or other substance abuse based on DSM-V criteria

Summary

Conditions
Autism Spectrum Disorders
Type
Observational
Design
  • Observational Model: Case-Control
  • Time Perspective: Prospective

Participation Requirements

Age
Between 3 years and 25 years
Gender
Both males and females

Description

Autism Spectrum Disorder Subject Criteria: Inclusion Criteria: Diagnosis of autism spectrum disorder, based upon a clinical interview utilizing the Diagnostic and Statistical Manual-V (DSM-V) Age 3-25 years Stable dosing of psychotropic drugs for greater than or equal to 5 half-lives Exclusion Crite...

Autism Spectrum Disorder Subject Criteria: Inclusion Criteria: Diagnosis of autism spectrum disorder, based upon a clinical interview utilizing the Diagnostic and Statistical Manual-V (DSM-V) Age 3-25 years Stable dosing of psychotropic drugs for greater than or equal to 5 half-lives Exclusion Criteria: Diagnosis of schizophrenia, another psychotic disorder, bipolar disorder, or alcohol or other substance abuse based on Diagnostic and Statistical Manual-V criteria Use of lithium, riluzole or other known modulators of ERK activation Age-Matched Neurotypical Control Subjects: Age matched to the age of an Autistic Disorder Subject History of normal development IQ-Matched Control Subjects: Those subjects who are included in the study based on having an IQ and age that matches the IQ and age of an Autistic Disorder Subject who has an IQ less than 70 All IQ-Matched Control Subjects will then also have an IQ less than 70

Inclusion Criteria

Stable dosing of psychotropic drugs for 5 half-lives or greater
Age 3-25 years
Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
Stable dosing of psychotropic drugs for 5 half-lives or greater
Age 3-25 years
Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V

Exclusion Criteria

Use of lithium, riluzole or other known modulators of ERK activation
Diagnosis of schizophrenia, another psychotic disorder, bipolar disorder, or alcohol or other substance abuse based on DSM-V criteria
Use of lithium, riluzole or other known modulators of ERK activation
Diagnosis of schizophrenia, another psychotic disorder, bipolar disorder, or alcohol or other substance abuse based on DSM-V criteria

Locations

Cincinnati, Ohio, 45229
Cincinnati, Ohio, 45229

Tracking Information

NCT #
NCT01850459
Collaborators
Not Provided
Investigators
  • Principal Investigator: Craig A. Erickson, M.D. Children's Hospital Medical Center, Cincinnati
  • Craig A. Erickson, M.D. Children's Hospital Medical Center, Cincinnati